MycoBiomDB – Record Details (MyCo_1324)

Biomarker Record Details

Database ID: MyCo_1324
DB IDMyCo_1324
TitleCombination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment
Year2015
PMID26311840
Fungal Diseases involvedInvasive candidiasis
Associated Medical ConditionNone
GenusCandida
Speciesalbicans
OrganismCandida albicans
Ethical StatementThe study was approved by the local ethics committee (CEIC-A1, ref. 247/ 13) and the Spanish Agency for Medicines and Health Care Products (Agencia Espan ˜ ola del Medicamento y Productos Sanitarios, AEMPS).
Site of InfectionNone
Opportunistic invasiveInvasive
Sample typeBody fluid
Sample sourceSerum
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker NameCAGTA
Biomarker Full NameCandida albicans germ tube antibody (CAGTA)
Biomarker TypeDiagnostic
BiomoleculeProtein
Geographical LocationSpain
CohortThis was a prospective observational study including adults starting empirical antifungal treatment for suspected IC, at Gregorio Maran ˜ o ´ n Hospital, Madrid (Spain). Patients were stratified according to admission department (ICU or other wards) and final diagnosis (no IC or proven or probable IC). Type of candidiasis (candi- daemia or deep-seated candidiasis) was also considered. Sixty-three ICU patients and 37 non-ICU patients were included.
Cohort No.63 Patients and 32 control
Age Group60.8±15.7
P ValueNone
Sensitivity0.6
Specificity0.857
Positive Predictive Value0.643
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismNone
TechniqueImmunological assay
Analysis MethodC. albicans germ tube antibody (CAGTA) assay (Vircell)
ELISA kitsNone
Assay DataNone
Validation Techniques usedCAGTA assay,FDA Approved-Fungitell assay
Up Regulation Down RegulationPositive
Sequence DataNone
External LinkNone